Less than 24 hours to go…

<p>It’s the eve of the election, and a lot is at stake for investors.</p><p>From tech regulation, to taxes and energy policy, there’s a ton riding on the outcome.</p><p>We’ll follow everything you need to know – including the record money pouring into campaigns, and all the possible outcomes for stocks in the coming days.</p><p>Plus, our own Meg Tirrell explains why Regeneron’s promising COVID-19 antibody treatment would be in short<strong> </strong>supply if the FDA approved it today. </p>